Management of invasive fungal infections in oncological patients

Onkologie

Volumn 22, Issue 3, 1999, Pages 192-197

  Bokemeyer, C ^b   Loffler J ^b   Schumacher, U ^b   Kanz, L ^b   Einsele, H ^b   Hebart, Holger ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b NONE

Author keywords

Antifungal drug; Disease management; Invasive fungal infection

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; NIKKOMYCIN; POSACONAZOLE; PRADIMICIN A; PYRROLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; ASPERGILLUS; BLOOD TOXICITY; BONE PAIN; CANCER PATIENT; DIARRHEA; FEVER; HUMAN; HYPOKALEMIA; KIDNEY TUBULE DAMAGE; MYCOSIS; NAUSEA; RASH; REVIEW; THROMBOPHLEBITIS;

EID: 0344327032     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026945     Document Type: Review

References (37)

1. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K: Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. Infect 1996;3:23-32.
2. Morrison VA, Haake RJ, Weisdorf DJ: Non-Candida fungal infections after bone marrow transplantation: Risk factors and outcome. Am J Med 1994;96: 497-503.
3. Grauer ME, Bokemeyer C, Welte T, Freund M, Link H: Successful treatment of Mucor pneumonia in a patient with relapsed lymphoblastic leukemia after bone marrow transplantation. Bone Marrow Transplant 1993;12:421.
4. Channock SJ, Pizzo PA: Infectious complications of patients undergoing therapy for acute leukemia: Current status and future prospects. Semin Oncol 1997;24:132-140.
5. Hebart H, Bokemeyer C, Löffler J, Schumacher U, Kanz L, Einsele H: New aspects for the diagnosis of invasive fungal diseae in oncological patients. Onkologie 1997;20:99-104.
6. Einsele H, Hebart H, Roller G, Löffler J, Rothenhöl'er I. Müller CA, Bowden RA, van Burik JA, Engelhard D, Kanz L, Schumacher U: Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997;35: 1353-1360.
7. Löffler J, Hebart H, Schumacher U, Reitze H, Einsele H: Comparison of different methods for extraction of DNA of fungal pathogens from cultures and blood. J Clin Microbiol 1997;35:3311-3312.
8. Kauffman CA, Carver PL: Antifungal agents in the 1990s. Drugs 1997;53:539-549.
9. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO, Williams T, Kontoyiannis DP, Karl CL, Bodey GP: Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-972.
10. Edwards JE, Bodey GP, Bowden RA, Buchner T, de Pauw BE, Filler SG, Ghannoum MA, Glauser M, Herbrecht R, Kauffman CA, Kohno S, Martino P, Meunier F, Mori T, Pfaller MA, Rex JH, Rogers TR, Rubin RH, Solomkin J, Viscoli C, Walsh TJ, White M: International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997;25: 43-59.
11. Van Burik JA, Bowden RA: Standard antifungal treatment, including role of alternative modalities to administer amphotericin B. Bailliere's Clin Infect Dis 1995;2:89-109.
12. Fisher MA, Talbot GH, Maislin G, McKeon BP, Tynan KP, Strom BL: Risk factors for amphotericin B-associated nephrotoxicity. Am J Med 1989;87: 547-552.
13. Walsh TJ: Management of immunocompromised patients with evidence of an invasive mycosis. Hematol Oncol Clin North Am 1993;7:1003-1026.
14. Grasela TH, Goodwin SD, Walawander MK, Cramer RL, Fuhs DW, Moriarty VP: Prospective surveillance of intravenous amphotericin B use patterns. Pharmacotherapy 1990;10:341-348.
15. Tynes BS, Utz JP, Bennett JE, Ailing DW: Reducing amphotericin B reactions. A double blind study. Am Rev Respir Dis 1963;87:264-268.
16. Kintzel PE, Smith GH: Practical guidelines for preparing and administering amphotericin B. Am J Hosp Pract 1992;49:1156-1164.
17. Kelly SL, Lamb DC, Kelly DE, Manning NJ, Loeffler J, Hebart H, Schumacher U, Einsele H: Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta (5,6) desaturation. FEBS Lett 1997;400:80-82.
18. Kelly SL, Lamb DC. Kelly DE, Loeffler J, Einsele H: Resistance to fluconazole and amphotericin B in Candida albicans from AIDS patients (letter). Lancet 1996;348:1523-1524.
19. Wingard JR: Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997;19:343-347.
20. Walsh T, Bodensteiner D, Hiemenz J, Thaler S, Greenberg R, Arndt C, Holcenberg J, Schwartz C, Pappas P, Dummer S, Marsh R, Schuster M, Seibel N, The Mycoses Study Group (MSG), and the Empirical Antifungal Study Group: LM-90 A randomized, double-blind trial of ambisome (liposomal amphotericin B) versus amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Abstract ICAAC 1997, Toronto, Canada.
21. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F. Oakhill A, Stevens RF, Darbyshire PJ, Gibson BE: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997;98:711-718.
22. Caillot D, Reny G, Solary E, Casanovas O, Chavanet P, Bonnotte B, Perello L, Mumas M, Entezam F, Guy H: A controlled trial of the tolerance of amphotericin B infused in dextrose or in intralipid in patients with hematologic malignancies. J Antimicrob Chemother 1994;33:603-613.
23. Clearly JD: Amphotericin B formulated in lipid emulsion. Ann Pharmacother 1996;30:409-412.
24. Martino P, Girmenia C: Are we making progress in antifungal therapy? Curr Opin Oncol 1997;9: 314-320.
25. Böhme A, Just-Nübling G, Bergmann L, Shah PM, Stille W, Hölzer D: Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1996;38:953-961.
26. Barry AL, Brown SD: In vitro studies of two triazole antifungal agents against Candida species. Antimicrob Agents Chemother 1996;40:1948-1949.
27. Graybill J: The future of antifungal therapy. Clin Infect Dis 1996;22:166-178.
28. Abruzzo GK, Flattery AM, Giill GJ, Kong L, Smith JG, Pikounis VB, Kropp H, Bartizal K: Evaluation of water-soluble pneumocandin analogs L-733560, L-705589 und L-731373 with mouse models of disseminated aspergillosis, candidiasis and cryptococcosis. Antimicrob Agents Chemother 1995;39: 1077-1081.
29. Kurtz MB, Bernard EM, Edwards FF, Marrinan J, Dropinski J, Douglas CM, Armstrong D: Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1995;39:1784-1789.
30. Tariq VN, Devlin PL: Sensitivity of fungi to nikkomycin Z. Fungal Genet Biol 1996;20:4-11.
31. Fung-Tomc JC, Minassian B, Huczko E, Kolek B, Bonner DP, Kessler RE: In vitro antifungal and fungicidal spectra of a new pradim ein derivative. BMS-181184. Antimicrob Agents Chemother 1995; 39:295-300.
32. Denning DW: Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-615.
33. Caillot D, Casasnovas O, Bernard A Couaillier JF; Durand C, Cuisenier B, Solary E, Piard F, Petrella T, Bonnin A, Couillault G, Dumas M, Guy H: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15:139-147.
34. Denning DW, Stevens DA: Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases. Rev Infect Dis 1990;12:1147-1201.
35. Denning DW, Lee JY, Hosteller JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A, Gallis H, Perfect JR, Dockery B, Dismukes WE, Stevens DA: NIAID Mycoses Study Group Multicenler Trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:135-144.
36. Hester JP, Dignani MC, Anaissie EJ, Kantarjian HM, O'Brien S, Freireich EJ: Collection and transfusion of granulocytc concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apheresis 1995;10:188-193.
37. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheid WM, Karchmer AW, Dine AP, Levenstein MJ, Webb CD: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Cand demia Study Group and the National Institute. N Engl J Med 1994;331:1325-1330.